Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
News|Articles|May 3, 2019
Eppendorf Hosts Vaccine Development and Bioprocess Cell Culture Technology Day
Author(s)Pharmaceutical Technology Editors
The Vaccine Development and Bioprocess Cell Culture Technology Day will take place on May 16, 2019 in Baltimore, MD.
Advertisement
Laboratory instrument and service provider Eppendorf announced that it will host the Vaccine Development and Bioprocess Cell Culture Technology Day on May 16, 2019 at the BWI Airport Marriott in Baltimore, MD. During the event, experts will discuss technologies in cell culture upstream bioprocess development with a special focus on perfusion technologies and scale-up.
“Today, scalable bioprocess systems, online process analytics, and process intensification are key for the development of robust, cost-efficient bioprocesses,” said Dr. Karl Rix, vice-president, business unit bioprocess, Eppendorf, in a company press release. “We are excited that bioprocess experts from Eppendorf, as well as representatives from Corning and other leading manufacturers, will share their latest bioprocess insights.”
For registration and further information, visit the
Source:
Advertisement
Related to this article
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Q&A: Patient-Centric Drug Development Should Start at Product Definition
3
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
4
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
5